Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient

Hande Akalan

doi:10.53433/yyufbed.1592435

TR EN

COVID-19’a Karşı Kullanılan Farmasötiklerin Kolorektal Adenokarsinom Hastasından Elde Edilen Hücre Dizisinde HDAC Aktivitesi ve Enflamasyon Üzerindeki Etkileri

Öz

Koronavirüs Hastalığı 2019 (COVID-19) pandemisinin tedavisinde çeşitli ilaçların farklı dozları kullanıldı. Bu ilaçlar doğrudan COVID-19 ile ilişkili olmadığından oluşturacakları etkilerin aydınlatılması oldukça önem taşımaktaydı. Yapılan araştırmalarla COVID-19'un kolorektal kanser ile yakından ilişkili olduğu ortaya konulmuştur. Gerçekleştirdiğimiz çalışmada kolorektal kanser hücre soyunda (Caco-2), COVID-19 tedavisinde kullanılan lopinavir/ritonavir, hidroksiklorokin, favipiravir, oseltamivir ilaç ve etken maddelerinin histon deasetilaz enzimi (HDAC) üzerindeki etkinlikleri ve enflamasyona katkıları araştırılmıştır. Böylece pandeminin kolorektal kanserle ilişkisine farklı bir bakış açısı kazandırmış olmak hedeflenmiştir. Bu çalışmada, uygulanan etken maddelerin Caco-2 hücrelerinin hücre canlılığı üzerindeki etkileri; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromid (MTT) analizi, akridin turuncusu/propidyum iyodür (AO/PI) boyaması kullanılarak belirlendi ve histon deasetilaz enzim aktivitesi HDAC testi ile saptandı. Ayrıca enflamatuvar etki, enzim bağlantılı immünosorbent testi (ELISA) kullanılarak interlökin 10 (IL-10), interlökin 6 (IL-6) ve tümör nekroz faktörü alfa (TNF-α) ekspresyon seviyelerinde meydana gelen değişiklere göre değerlendirildi. Uygulama yapılan gruplarda hücre canlılığı devam ederken, HDAC enzim aktivitesinde artış meydana geldi. Bu artışın IL-6 ekspresyonu üzerinde etkili olduğu gösterilerek enflamasyona neden olduğu düşünülmektedir.

Anahtar Kelimeler

Favipiravir, HDAC, Hidroksiklorokin, Lopinavir/ritonavir, Oseltamivir, Valproik asit

Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient

Öz

Different doses of various drugs were used in the treatment of the Coronavirus Disease 2019 (COVID-19) pandemic that affected the whole world. Since these drugs are not directly related to COVID-19, it was very important to elucidate their effects. Studies have shown that COVID-19 is closely related to colorectal cancer. Our study examines the effects of Lopinavir/ritonavir, hydroxychloroquine, favipiravir, and oseltamivir, as well as their active ingredients used during COVID-19 treatment, on the histone deacetylase enzyme (HDAC) in colorectal cancer cells. Thus, it is aimed to provide a different perspective on the relationship between pandemic and colorectal cancer. In this study, the effects of the applied drugs on cell viability were evaluated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) analysis, acridine orange/propidium iodide (AO/PI) staining and histone deacetylase enzyme activity was evaluated in colorectal adenocarcinoma cell line (Caco-2) with HDAC assay. Using an enzyme-linked immunosorbent assay (ELISA), the inflammatory effects on the cells due to the application were assessed based on the expression levels of interleukin 10 (IL-10), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α). Experimental groups showed continued cell viability, and an increase in HDAC enzyme activity was observed. This increase was found to effectively influence the IL-6 expression, which is believed to enhance inflammation.

Anahtar Kelimeler

Favipiravir, HDAC, Hydroxychloroquine, Lopinavir/ritonavir, Oseltamivir, Valproic acid

Kaynakça

Agrawal, S., Goel, A. D., & Gupta, N. (2020). Emerging prophylaxis strategies against COVID-19. Monaldi Archives for Chest Disease, 90(1). https://doi.org/10.4081/monaldi.2020.1289
Al-Quteimat, O. M., Amer, A. M. (2020). The impact of the Covid-19 pandemic on cancer patients. American Journal of Clinical Oncology, 43, 452-455. https://doi.org/10.1097/COC.0000000000000712
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q.,Yang, Y., Shen, C., Li, X., Peng, L., Huang, D., Zhang, J., Zhang, S.,Wang, F., Liu, J., Chen, L., Chen, S., Wang, Z., Zhang, Z., Cao, R., Zhong, W., Liu, Y., & Liu, L. (2020). Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering, 6(10), 1192-1198. https://doi.org/10.1016/j.eng.2020.03.007
Cao, W., Fang, Z., Hou, G., Han, M., Xu, X., Dong, J., & Zheng, J. (2020). The psychological impact of the COVID-19 epidemic on college students in China. Psychiatry Research, 287, 112934. https://doi.org/10.1016/j.psychres.2020.112934
Cvetkovic, R. S., & Goa, K. L. (2003). Lopinavir/ritonavir: a review of its use in the management of HIV infection. Review Drugs, 63(8), 769-802. https://doi.org/10.2165/00003495-200363080-00004
Gallinari, P., Marco, S., Jones, P., Pallaoro, M. & Steinkühler. C. (2007). HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Research, 17, 195-211. https://doi.org/10.1038/sj.cr.7310149
Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends, 14(1), 72-73. https://doi.org/10.5582/bst.2020.01047
Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Dupont, H. T., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. International Journal of Antimicrobial Agents, 56, 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
Guzelel, G., Akalan, H., Bilgen, T., & Yasar Sirin, D. (2024). Investigation of the effects of piperlongumine and doxorubicin combined treatment on cell death via PTEN in HeLa cells. Yuzuncu Yil University Journal of the Institute of Natural & Applied Sciences, 29(1), 1-11. https://doi.org/10.53433/yyufbed.1258515
Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., & Martinez-de-Hoyo, R. (2021). The efficacy and safety of favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Scientific Reports, 11(1), 11022. https://doi.org/10.1038/s41598-021-90551-6

Hu, Q., Greene, C. S., & Heller, E. A. (2020). Specific histon modifications associate with alternative exon selection during mammalian development. Nucleic Acids Research, 48(9), 4709-4724. https://doi.org/10.1093/nar/gkaa248
Jordan, P. C., Stevens, S. K., & Deval, J. (2018). Nucleosides for the treatment of respiratory RNA virus infections. Antiviral Chemistry and Chemotherapy, 26. https://doi.org/10.1177/2040206618764483
Kany, S., Vollrath, J. T., & Relja, B. (2019). Cytokines in inflammatory disease. International Journal of Molecular Science, 20(23), 6008. https://doi.org/10.3390/ijms20236008
Khangura, R. K., Bali, A., Jaggi, A. S., & Singh, N. (2017). Histone acetylation and histone deacetylation in neuropathic pain: An unresolved puzzle?. European Journal of Pharmacology, 795, 36-42. https://doi.org/10.1016/j.ejphar.2016.12.001
Kaya, Y. E., Akalan, H., Yilmaz, I., Karaaslan, N., Yasar Sırın, D., & Ozbek, H. (2020). Evaluation of the expression and proliferation of degenerative markers in primary cell cultures obtained from human intervertebral disc tissue. Annals of Medical Research, 27(3), 711-6. https://doi.org/10.5455/annalsmedres.2020.02.171
Kaya, Y. E., Yilmaz, I., Albayrak, M., Yilmaz, O. F., & Yasar Sirin, D. (2024). The effect of favipiravir on histone deacetylase (HDAC) enzyme activity in administered to human primary chondrocyte cultures and an evaluation of its relationship with inflammation. Experimental Biomedical Research, 7(4), 255-267. https://doi.org/10.30714/j-ebr.2024.228
Kucukoglu, K. (2013). Acetylation of histones and histone deacetylase inhibitors: Review. Turkiye Klinikleri Journal of Literature Pharmacy Sciences, 2(2), 55-73.
Kulkarni, V. S., Alagarsamy V., Solomon V. R., Jose P. A., & Murugesan, S. (2023). Drug repurposing: an effective tool in modern drug discovery. Russian Journal of Bioorganic Chemistry, 49(2), 157-166. https://doi.org/10.1134/S1068162023020139
Li, G., & De Clercq, E. (2020). Therapeutic options for the 2019 novel coronavirus (2019-ncov). Nature Reviews Drug Discovery, 19(3), 149-150. https://doi.org/10.1038/d41573-020-00016-0
Page, J., Hinshaw, D., & Mckay, B. (2021). In hunt for Covid-19 origin, patient zero points to second Wuhan Market – The man with the first confirmed infection of the new coronavirus told the WHO team that his parents had shopped there. The Wall Street Journal. https://www.wsj.com/articles/in-hunt-for-covid-19-origin-patient-zero-points-to-second-wuhan-market-11614335404
Roostaee, A., Guezguez, A., Beauséjour, M., Simoneau, A., Vachon, P. H., Levy, E., & Beaulieu, J. F. (2015). Histone deacetylase inhibition ımpairs normal intestinal cell proliferation and promotes specific gene expression. Journal of Cell Biochemistry, 116(11), 2695-2708. https://doi.org/10.1002/jcb.25274
Sanders, J. M., Monogue, M. L., Jodlowski T. Z., & Cutrell, J. B. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA, 323(18), 1824-1836. https://doi.org/10.1001/jama.2020.6019
Shiraki, K., & Daikoku, T. (2020). Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & Therapeutics, 209, 107512. https://doi.org/10.1016/j.pharmthera.2020.107512
Shiraki, K., Sato, N., Sakai, K., Matsumoto, S., Kaszynski, R. H., & Takemoto, M. (2022). Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences. Pharmacology & Therapeutics, 235, 108121. https://doi.org/10.1016/j.pharmthera.2022.108121
Singh, A. K., Bishayee, A., & Pandey, A. K. (2018). Targeting histone deacetylases with natural and synthetic agents: An emerging anticancer strategy. Nutrients, 10(6), 731. https://doi.org/10.3390/nu10060731
Song, Y., Huang, T., Pan, H., Du, A., Wu, T., Lan, J., Zhou, X., Lv, Y., Xue, S., & Yuan, K. (2023). The influence of COVID-19 on colorectal cancer was investigated using bioinformatics and systems biology techniques. Frontiers in Medicine, 30(10), 1169562. https://doi.org/10.3389/fmed.2023.1169562
Swift, R., & Feast, L. (2021). Fujifilm's Avigan shows no significant benefit on COVID-19 mortality: study. Reuters. Tokyo. https://www.reuters.com/article/us-health-coronavirus-fujifilm-avigan/fujifilms-avigan-shows-no-significant-benefit-on-covid-19-mortality-study-idUSKBN2AI0SK/
Terzioglu Bebitoglu, B., Oğuz, E., Hodzic, A., Hatiboğlu, N., & Kam, O. (2020). Chloroquine/Hydroxychloroquine: pharmacological view of an old drug currently used in COVID-19 treatment. Anadolu Kliniği Tıp Bilimleri Dergisi, 25-1. https://doi.org/10.21673/anadoluklin.735826
Tsai, C. H., Li, C. H., Liao, P. L., Chang, Y. W., Cheng, Y. W., & Kang, J. J. (2020). Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via pkcα-mediated AHR-HDAC interactions. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1867(2), 118564. https://doi.org/10.1016/j.bbamcr.2019.118564
Vitkus, S. V., Hanifin, S. A., & McGee, D. W. (1998). Factors affecting Caco-2 intestinal epithelial cell interleukin-6 secretion. In Vitro Cellular & Developmental Biology – Animal, 34(8), 660-4. https://doi.org/10.1007/s11626-996-0017-7
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu. Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-ncov) in vitro. Cell Research, 30, 269-271. https://doi.org/10.1038/s41422-020-0282-0
Yao, T. T., Qian, J. D., Zhu, W. Y., Wang, Y., & Wang, G. Q. (2020). A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. Journal of Medical Virology, 92(6), 556-563. https://doi.org/10.1002/jmv.25729
Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., Ng, O. T., Marimuthu, K., Ang, L. W., Mak, T. M., Lau, S. K., Anderson, D. E., Chan, K. S., Tan, T. Y., Ng, T. Y., Cui, L., Said, Z., Kurupatham, L., Chen, M. I., Chan, M., Vasoo, S., Wang, L. F., Tan, B. H., Lin, R. T. P., Lee, V. J. M., Leo, Y. S., Lye, D. C., & Singapore 2019 Novel Coronavirus Outbreak Research Team. (2020). Epidemiologic features and clinical course of patients ınfected with SARS-cov-2 in Singapore. JAMA, 323(15), 1488-1494. https://doi.org/10.1001/jama.2020.3204
Yousefi, H., Mashouri, L., Okpechi, S. C., Alahari, N., & Alahari, S. K. (2021). Repurposing existing drugs for the treatment of COVID-19/SARS-cov-2 infection: a review describing drug mechanisms of action. Biochemical Pharmacology, 13, 114296. https://doi.org/10.1016/j.bcp.2020.114296
Zendehdel, A., Bidkhori, M., Ansari, M., Jamalimoghaddamsiyahkali, S., & Asoodeh, A. (2022). Efficacy of oseltamivir in the treatment of patients infected with Covid-19. Annals of Medicine & Surgery, 77, 103679. https://doi.org/10.1016/j.amsu.2022.103679
Zhao, Z., & Shilatifard, A. (2019). Epigenetic modifications of histones in cancer. Genome Biology, 20(1), 245. https://doi.org/10.1186/s13059-019-1870-5

Ayrıntılar

Birincil Dil

İngilizce

Konular

Epigenetik , Hayvan Hücresi ve Moleküler Biyoloji

Bölüm

Araştırma Makalesi

Yazarlar

Hande Akalan ^*
0000-0002-5922-2498
Türkiye

Yayımlanma Tarihi

29 Nisan 2025

Gönderilme Tarihi

28 Kasım 2024

Kabul Tarihi

12 Aralık 2024

Yayımlandığı Sayı

Yıl 2025 Cilt: 30 Sayı: 1

DOI

https://doi.org/10.53433/yyufbed.1592435

IZ

https://izlik.org/JA72KU67AY

APA

Akalan, H. (2025). Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient. Yüzüncü Yıl Üniversitesi Fen Bilimleri Enstitüsü Dergisi, 30(1), 1-12. https://doi.org/10.53433/yyufbed.1592435

AMA

1.Akalan H. Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient. YYUFBED. 2025;30(1):1-12. doi:10.53433/yyufbed.1592435

Chicago

Akalan, Hande. 2025. “Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient”. Yüzüncü Yıl Üniversitesi Fen Bilimleri Enstitüsü Dergisi 30 (1): 1-12. https://doi.org/10.53433/yyufbed.1592435.

EndNote

Akalan H (01 Nisan 2025) Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient. Yüzüncü Yıl Üniversitesi Fen Bilimleri Enstitüsü Dergisi 30 1 1–12.

IEEE

[1]H. Akalan, “Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient”, YYUFBED, c. 30, sy 1, ss. 1–12, Nis. 2025, doi: 10.53433/yyufbed.1592435.

ISNAD

Akalan, Hande. “Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient”. Yüzüncü Yıl Üniversitesi Fen Bilimleri Enstitüsü Dergisi 30/1 (01 Nisan 2025): 1-12. https://doi.org/10.53433/yyufbed.1592435.

JAMA

1.Akalan H. Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient. YYUFBED. 2025;30:1–12.

MLA

Akalan, Hande. “Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient”. Yüzüncü Yıl Üniversitesi Fen Bilimleri Enstitüsü Dergisi, c. 30, sy 1, Nisan 2025, ss. 1-12, doi:10.53433/yyufbed.1592435.

Vancouver

1.Hande Akalan. Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient. YYUFBED. 01 Nisan 2025;30(1):1-12. doi:10.53433/yyufbed.1592435

COVID-19’a Karşı Kullanılan Farmasötiklerin Kolorektal Adenokarsinom Hastasından Elde Edilen Hücre Dizisinde HDAC Aktivitesi ve Enflamasyon Üzerindeki Etkileri

Öz

Anahtar Kelimeler

Effects of Pharmaceuticals Used Against COVID-19 on HDAC Activity and Inflammation in Cell Line Obtained from a Colorectal Adenocarcinoma Patient

Öz

Anahtar Kelimeler

Kaynakça

Ayrıntılar

Birincil Dil

Konular

Bölüm

Yazarlar

Yayımlanma Tarihi

Gönderilme Tarihi

Kabul Tarihi

Yayımlandığı Sayı

DOI

IZ

Kaynak Göster